Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

JTC Team to Host Virtual Investor Niemann-Pick Disease Type C Spotlight Event Featuring Cyclo Therapeutics

- Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday, May 16th at 2:00 PM ET -

FRENCHTOWN, NJ / ACCESSWIRE / May 12, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Niemann-Pick Disease Type C (NPC) Spotlight Event Featuring Cyclo Therapeutics on Monday, May 16, 2022 at 2:00 PM ET. Access the event here.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) is a late clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. As part of the event, Cyclo Therapeutics will discuss NPC, a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells, and its ongoing development program of Trappsol® Cyclo™ for the treatment of NPC. Trappsol® Cyclo™ is the Company's proprietary formulation of hydroxypropyl beta cyclodextrin, used intravenously (IV), which in multiple clinical studies has shown encouraging results to normalize the transportation of cholesterol in cells.

For the discussion, Lise Lund Kjems, MD, PhD, Chief Medical Officer and Lori McKenna Gorski, Global Head of Patient Advocacy of Cyclo Therapeutics will be joined by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company's ongoing TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of NPC.

JTC Team, LLC, Thursday, May 12, 2022, Press release picture

Dr. Hastings currently serves as the Pediatric hematologist oncologist, Director of Neuro-oncology, and Professor of Pediatrics at UCSF Benioff Children's Hospital Oakland and is an advisor to U.S. and Australian NPC Advocacy organizations and to physicians globally on NPC. She has been practicing in the field of Pediatric Hematology Oncology since 1992 and has served as the director of the fellowship program at the Children's Hospital & Research Center Oakland since 1996. She has devoted herself to her patients and to fostering education in this specialty. Her academic interests include tumors of the brain and spinal cord, relapsed acute lymphoblastic leukemia, and lysosomal storage diseases including Niemann Pick Type C disease.

A live video webcast of the Virtual Investor Niemann-Pick Disease Type C Spotlight Event Featuring Cyclo Therapeutics will be available on virtualinvestorco.com. A webcast replay will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

JTC Team, LLC, Thursday, May 12, 2022, Press release picture


About JTC Team

JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

Contact:

Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com

SOURCE: JTC Team, LLC



View source version on accesswire.com:
https://www.accesswire.com/701115/JTC-Team-to-Host-Virtual-Investor-Niemann-Pick-Disease-Type-C-Spotlight-Event-Featuring-Cyclo-Therapeutics

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.